Company Filing History:
2 out of 3,221 
1 out of 39 
Years Active: 2021-2024
Title: Christiaan Nicolaas Klijn: Innovator in Cancer Diagnostics and Treatment
Introduction
Christiaan Nicolaas Klijn is a prominent inventor based in San Francisco, CA, known for his significant contributions to cancer diagnostics and treatment. With a total of two patents to his name, Klijn has focused on developing innovative methods that enhance the understanding and treatment of cancer.
Latest Patents
Klijn's latest patents include groundbreaking diagnostic and therapeutic methods for cancer. One patent provides methods for determining whether an individual with cancer is likely to respond to treatment involving a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor. This invention also outlines methods for predicting responsiveness to treatment and selecting appropriate therapies based on the presence of specific biomarkers, such as KRAS or NRAS activating mutations. Another patent focuses on diagnosing and treating cancer by analyzing the expression status and mutational status of NRF2 and its downstream target genes. This invention offers methods for identifying subjects with lung cancer and treating them with NRF2 pathway antagonists.
Career Highlights
Throughout his career, Klijn has worked with notable companies in the biotechnology sector, including Genentech, Inc. and Foundation Medicine, Inc. His work in these organizations has contributed to advancements in cancer research and treatment methodologies.
Collaborations
Klijn has collaborated with esteemed colleagues, including James M. Lee and David Hugh Stokoe, further enhancing the impact of his work in the field of cancer diagnostics and treatment.
Conclusion
Christiaan Nicolaas Klijn's innovative patents and career achievements underscore his commitment to improving cancer treatment and diagnostics. His contributions continue to influence the field and offer hope for better patient outcomes.